Adverse Event reporting information can be found in footer

PAEDIATRIC FORMULATIONS

Request a Meeting

PAEDIATRIC FORMULATIONS

PENTASA® FORMULATIONS TO SUIT YOUR PAEDIATRIC* PATIENTS’ NEEDS

The following oral PENTASA® formulations are licensed for achieving and maintaining remission in children from the age of 6 and upwards: 1-5

500mg-tablets-web

1g sachet

500mg-tablets-web

2g sachet

500mg-tablets-web

4g sachet

500mg-tablets-web

500mg tablet

500mg-tablets-web

1g tablet

*All PENTASA® oral presentations are licensed for children from six years of age and given in divided doses.

 

DOSING GUIDANCE

Active:

Starting – give 30-50mg per kg per day in divided doses.

Maximum dose = 75mg per kg per day in divided doses.

Total dose not to exceed 4g per day.

MAINTENANCE:

Starting – give 15-30mg per kg per day in divided doses.

Total dose not to exceed 2g per day.

  • Generally it’s recommended that half the adult dose may be given to children up to 40kg; and the normal adult dose to those >40kg

PENTASA® PROVIDES FLEXIBLE ADMINISTRATION

TO AID WITH SWALLOWING:

500mg-tablets-web

Sachets can be incorporated into yoghurt or washed down with water or orange juice3-5

500mg-tablets-web

Granules can be washed down with water or orange juice3-5

500mg-tablets-web

Tablets can be broken1

500mg-tablets-web

Tablets can be dispersed in 50ml of cold water1,2

PENTASA® IS ALSO FLEXIBLE AS:

500mg-tablets-web

It doesn’t need to be taken at meal times because PENTASA®’s unique ethyl cellulose coated microgranules release mesalazine at all enteral pH conditions, independent of food co-administration1-17

500mg-tablets-web

Delivery is only slightly affected by diarrhoea1-5

  • Pentasa Slow Release Tablets 500 mg. SmPC.
  • Pentasa Slow Release Tablets 1 g. SmPC.
  • Pentasa Sachet 1 g. SmPC.
  • Pentasa Sachet 2 g. SmPC.
  • Pentasa Sachet 4 g. SmPC.
  • Salofalk® 250 mg MR Tablets. SmPC.
  • Salofalk® 500 mg Tablets. SmPC.
  • Salofalk® 500 mg Gastro-resistant Prolonged Release Granules. SmPC.
  • Salofalk® 1 g Tablets. SmPC.
  • Salofalk® 1 g Gastro-resistant Prolonged Release Granules. SmPC.
  • Salofalk® 1.5 g Gastro-resistant Prolonged Release Granules. SmPC.
  • Salofalk® 3 g Gastro-resistant Prolonged Release Granules. SmPC.
  • Sulfasalazine 250 mg/5 ml Oral Suspension. SmPC.
  • Octasa® 400 mg MR Tablets. SmPC.
  • Octasa® 800 mg MR Tablets. SmPC.
  • Salazopyrin Tablets. SmPC.
  • Salazopyrin En-Tabs. SmPC.

Job Code: UK-PA-2400044 - Date of preparation: November 2024

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.